The global cell-based assays market is set to grow from USD 17.84 billion in 2025 to USD 27.55 billion by 2030, marking a ...

Pharmacokinetics (PK) in critically ill patients can be highly variable, demanding individualised dosing strategies to achieve therapeutic efficacy while minimising toxicity.

CorestemChemon (KOSDAQ: 166480) is a full-service preclinical CRO with over two decades of experience in GLP-based toxicology ...

The investigational oral pre-exposure prophylaxis (PrEP) agent MK-8527 showed a similar, well-tolerated safety profile to ...

Cigarette smoke contains compounds that significantly affect drug interactions in clinical settings, primarily through the induction of cytochrome P450 (CYP) enzymes. Given the complexity of cigarette ...

7月18日，国家药品监督管理局官网显示，抗流感1类创新药济可舒（通用名：玛硒洛沙韦片）获批上市。济可舒作为新型靶向流感病毒RNA聚合酶PA抑制剂，全疗程1次用药，1天退热，不良反应少。此次获批不仅标志着我国抗流感药物创新研发的重要突破，也为患者应对流 ...

Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery ...

The decision follows the initial approval granted in September 2023, which covered patients aged five years and above.

The FDA clears GL-IL2-138, a groundbreaking oral drug modulating natural IL-2, set to revolutionize treatment in oncology.

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

Researchers found that Halicin, an AI-identified drug, effectively inhibited most multidrug-resistant bacteria except ...

Astria Therapeutics' Navenibart shows promise in phase 3 trials for hereditary angioedema. Click here to find out why ATXS ...